AbbVie Reports Third-Quarter 2026 Financial Results

AbbVie posts over 100% EPS growth, raises 2026 guidance, and boosts 2027 dividend.

What the company is saying

AbbVie emphasizes strong financial and operational performance for Q3 2026, highlighting a more than doubling of both GAAP diluted EPS ($2.37) and adjusted diluted EPS ($3.82). The company attributes these results to robust execution across its portfolio, with CEO Robert A. Michael directly quoted on the company's momentum and enhanced long-term growth prospects. The announcement foregrounds a 10.3% increase in net revenues to $17.404 billion, with immunology and neuroscience portfolios driving growth. AbbVie spotlights the completed acquisition of Apogee Therapeutics as a strategic move to deepen its immunology pipeline, specifically naming new assets zumilokibart and APG273. The company raises its 2026 adjusted EPS guidance to $13.95–$13.99, incorporating a $0.69 per share unfavorable impact from acquired IPR&D and milestones expense. A 5.2% dividend increase for 2027, effective with the February 2027 payout, is announced as a signal of confidence. The release also details recent regulatory approvals, clinical trial milestones, and ongoing pipeline progress, presenting a tone of sustained growth and operational discipline.

What the data suggests

The numbers reveal a company in strong financial health: Q3 2026 GAAP diluted EPS rose over 100% to $2.37, with adjusted diluted EPS also up over 100% to $3.82, despite a $0.11 per share drag from acquired IPR&D and milestones expense. Net revenues climbed 10.3% to $17.404 billion, with immunology revenues up 16.3% to $9.165 billion, led by Skyrizi ($5.776 billion, up 22.7%) and Rinvoq ($2.706 billion, up 23.9%), while Humira fell 31.2% to $683 million. Neuroscience revenues rose 19.4% to $3.389 billion, with Vraylar at $1.068 billion and Botox Therapeutic at $1.080 billion. Oncology revenues were stable at $1.696 billion, with Venclexta up 10.7% to $803 million and Imbruvica down 26.1% to $522 million. Aesthetics revenues declined 1.4% to $1.176 billion, with Juvederm down 11.9% to $222 million. The company maintains high margins: GAAP gross margin at 75.4%, adjusted at 85.1%, and adjusted operating margin at 48.7%. Net interest expense was $700 million GAAP ($688 million adjusted), and the tax rate was 12.6% GAAP (13.6% adjusted). The raised 2026 EPS guidance ($13.95–$13.99) signals management's confidence, while the 5.2% dividend hike for 2027 provides tangible shareholder return. Pipeline progress is evidenced by FDA approvals, positive late-stage trial results, and regulatory submissions, though some clinical data are pending further disclosure.

Analysis

AbbVie's announcement is grounded in realised, measurable financial and operational results for Q3 2026, including over 100% growth in both GAAP and adjusted EPS, a 10.3% increase in net revenues, and robust margin disclosures. The company provides detailed breakdowns by therapeutic area and product, with clear growth rates and profitability metrics, satisfying the requirements for a strong_positive signal. While there are some forward-looking elements—such as raised 2026 EPS guidance, a 2027 dividend increase, and future regulatory submissions—these are proportionate and supported by the company's current performance and completed milestones (e.g., Apogee acquisition, FDA approvals). The tone is positive but not exaggerated, and there is no evidence of narrative inflation or overstatement relative to the disclosed data. No large capital outlay is paired with only long-dated, uncertain returns; the Apogee acquisition is completed and integrated into the pipeline. The majority of claims are realised, with only a small fraction being forward-looking projections.

Risk flags

• ●Revenue concentration risk is evident, as Skyrizi and Rinvoq now represent a growing share of immunology revenues, while legacy product Humira declined 31.2% to $683 million. Overreliance on a few high-growth assets could expose AbbVie to future competitive or regulatory pressures.
• ●Pipeline execution risk remains, with several late-stage assets (e.g., lutikizumab, etentamig) still pending regulatory approvals and additional data readouts. Delays or negative outcomes in these programs could impact future growth assumptions.
• ●Aesthetics portfolio softness is a concern, as revenues declined 1.4% and Juvederm fell 11.9%, signaling either market saturation or competitive headwinds in this segment.
• ●Integration risk from the Apogee Therapeutics acquisition exists, as the value realization from new pipeline assets (zumilokibart, APG273) depends on successful development and commercialization, which is inherently uncertain.
• ●While margins and cash flow are strong, net interest expense remains high at $700 million GAAP for the quarter, reflecting a significant debt load that could limit flexibility if macro conditions worsen.

Bottom line

AbbVie delivers a robust quarter, with over 100% growth in both GAAP and adjusted EPS and a 10.3% rise in net revenues, driven by immunology and neuroscience. The company raises its 2026 adjusted EPS guidance to $13.95–$13.99 and announces a 5.2% dividend increase for 2027, reinforcing management's confidence in sustained earnings and cash flow. Key pipeline and regulatory milestones, including the Apogee Therapeutics acquisition and multiple FDA approvals, support the long-term growth narrative, though some late-stage assets will not contribute until at least 2027. Risks include product concentration in immunology, declining legacy and aesthetics revenues, and the need for successful pipeline execution. The evidence supports AbbVie's positive outlook, but investors should monitor the performance of new assets and the impact of high debt service. The most important takeaway is AbbVie's ability to offset legacy declines with high-growth assets and deliver immediate shareholder value while investing for future expansion.

Announcement summary

(NYSE:ABBV) AbbVie reported third-quarter diluted EPS of $2.37 on a GAAP basis, representing an increase of over 100.0 percent, and adjusted diluted EPS of $3.82, also an increase of over 100.0 percent. These results include an unfavorable impact of $0.11 per share related to acquired IPR&D and milestones expense. Third-quarter net revenues were $17.404 billion, an increase of 10.3 percent on a reported basis or 10.5 percent on an operational basis. Global net revenues from the immunology portfolio were $9.165 billion, up 16.3 percent reported and 16.6 percent operationally, with Skyrizi net revenues at $5.776 billion, Rinvoq at $2.706 billion, and Humira at $683 million. Neuroscience portfolio global net revenues were $3.389 billion, up 19.4 percent reported and 19.5 percent operationally, with Vraylar at $1.068 billion, Botox Therapeutic at $1.080 billion, combined Ubrelvy and Qulipta at $847 million, and Vyalev at $286 million. Oncology portfolio global net revenues were $1.696 billion, up 0.8 percent reported and 0.9 percent operationally, with Venclexta at $803 million, Imbruvica at $522 million, and Elahere at $224 million. Aesthetics portfolio global net revenues were $1.176 billion, down 1.4 percent reported and 1.8 percent operationally, with Botox Cosmetic at $669 million and Juvederm at $222 million. The company completed the acquisition of Apogee Therapeutics, adding assets such as zumilokibart and APG273 to its immunology pipeline. AbbVie raised its 2026 adjusted diluted EPS guidance range from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026. AbbVie announced a 2027 dividend increase of 5.2 percent, beginning with the dividend payable in February 2027. On a GAAP basis, the gross margin ratio in the third quarter was 75.4 percent, and the adjusted gross margin ratio was 85.1 percent. GAAP SG&A expense was 23.5 percent of net revenues, adjusted SG&A was 21.2 percent, GAAP R&D expense was 14.7 percent, and adjusted R&D was 13.9 percent. Acquired IPR&D and milestones expense was 1.2 percent of net revenues. GAAP operating margin ratio was 36.0 percent, adjusted operating margin ratio was 48.7 percent. GAAP net interest expense was $700 million, adjusted net interest expense was $688 million. GAAP tax rate was 12.6 percent, adjusted tax rate was 13.6 percent. The company announced FDA approval of Skyrizi for subcutaneous induction in Crohn's disease, and an update to Skyrizi's U.S. prescribing information. AbbVie submitted an application to the EMA for Skyrizi for SC induction in Crohn's disease. Positive topline results were announced from the Phase 3 INTREPID study of lutikizumab in hidradenitis suppurativa, meeting primary and most secondary endpoints. Additional data from this study, including a 36-week extension, are expected next year and will support regulatory submissions for lutikizumab in HS in the second half of 2027. At the ACG 2026 Annual Scientific Meeting, AbbVie presented new Skyrizi and Rinvoq data for IBD, including Phase 3 AFFIRM data and real-world studies. At the 2026 UEG Week, AbbVie presented 20 IBD research presentations, including late-breaking results from the Phase 2a TARGET-CD trial for ABBV-466 (Skyrizi + ABBV-382) combination therapy. At the 2026 EADV Congress, AbbVie presented data from 60 abstracts, including Phase 3 Viti-Up-1 and Viti-Up-2 studies of Rinvoq in non-segmental vitiligo, and Phase 2 APEX Part B study of zumilokibart in atopic dermatitis. The FDA approved Juvmo (tavapadon) tablets for Parkinson's disease, supported by the Phase 3 TEMPO program. Positive topline results were announced from the Phase 3 LUNA study of Qulipta for menstrual migraine. At Psych Congress 2026, new real-world data for Vraylar were presented. AbbVie submitted a BLA to the FDA for etentamig for relapsed/refractory multiple myeloma, supported by Phase 3 CERVINO study results showing ORR of 74% and PFS of 60%. AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial of Epkinly in combination with R-CHOP, reducing risk of disease progression or death by 51%. The FDA granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A).

Disagree with this article?